Addpharma Inc.

Quick facts

Marketed products

• Ezetimibe/Rosuvastatin · Cardiovascular
  This combination reduces cholesterol by blocking intestinal cholesterol absorption (ezetimibe) and inhibiting HMG-CoA reductase to decrease hepatic cholesterol synthesis (rosuvastatin).

Phase 3 pipeline

• AD-2021 · Oncology
  AD-2021 is a small molecule that targets the PI3K/AKT pathway to inhibit cancer cell growth.
• AD-2022 · Oncology
  AD-2022 is a small molecule that targets the PI3K/AKT pathway.
• AD-203 · Infectious Disease
  AD-203 is a small molecule that targets the SARS-CoV-2 main protease.
• AD-208 · Diabetes
  AD-208 is a small molecule that targets the SGLT2 receptor.
• AD-2081 · Diabetes
  AD-2081 is a small molecule that targets the SGLT2 receptor.
• AD-209 · Diabetes
  AD-209 is a small molecule that targets the SGLT2 receptor.
• AD-2091 · Oncology
  AD-2091 is a small molecule that targets the PI3K/AKT pathway to inhibit cancer cell growth.
• AD-218 · Diabetes
  AD-218 is a small molecule that targets the SGLT2 receptor.
• AD-218A · Diabetes
  AD-218A is a small molecule that targets the SGLT2 receptor.
• AD-221 · Autoimmune diseases
  AD-221 is a small molecule inhibitor of the PI3K delta subunit.
• AD-221A · Oncology
  AD-221A is a small molecule that targets the PD-1 receptor.
• AD-221B · Oncology
  AD-221B is a small molecule that targets the PD-1 receptor.
• AD-221C · Oncology
  AD-221C is a small molecule that targets the PD-1 receptor.
• AD-223A · Oncology
  AD-223A is a small molecule that targets the PD-1 receptor.
• AD-223B · Oncology
  AD-223B is a small molecule that targets the PD-1 receptor.
• AD-223C · Oncology
  AD-223C is a small molecule that targets the PD-1 receptor.
• AD-224A · Diabetes
  AD-224A is a small molecule that targets the SGLT2 receptor.
• AD-224B · Diabetes
  AD-224B is a small molecule that targets the SGLT2 receptor.
• AD-224C · Diabetes
  AD-224C is a small molecule that targets the SGLT2 receptor.
• AD-227A · Psychiatry
  AD-227A is a small molecule drug that targets the serotonin receptor.
• AD-227B · Psychiatry
  AD-227B is a small molecule that targets the serotonin receptor 5-HT2A.
• AD-227C · Psychiatry
  AD-227C is a small molecule drug that targets the serotonin receptor.
• AD-2281 · Oncology
  AD-2281 is a small molecule that targets the PI3K/AKT pathway.
• AD-2282 · Oncology
  AD-2282 is a small molecule that targets the PD-1 receptor.
• placebo of AD-208
  This is a placebo, meaning it has no active pharmacological effect.
• placebo of AD-2081
  This drug is a placebo for AD-2081, meaning it has no active therapeutic effect.
• Placebo of AD-224A
  This is a placebo, meaning it has no active therapeutic effect.
• Placebo of AD-224B
  This is a placebo control formulation used in clinical trials and contains no active pharmaceutical ingredient.
• Placebo of AD-224C
  This is a placebo control formulation used in clinical trials and contains no active pharmaceutical ingredient.
• Placebo of AD-227B
  This is a placebo control formulation with no active pharmacological mechanism.
• Placebo of AD-227C
  This is a placebo control formulation with no active pharmacological mechanism.
• Placebo of AD-2282
  This drug is a placebo, meaning it has no active therapeutic effect.

Phase 2 pipeline

• AD-209-1A
• AD-209-1B · Diabetes
  AD-209-1B is a small molecule that targets the SGLT2 receptor.
• AD-209-1C
• AD209
• Amlodipine low · Cardiovascular
  Amlodipine is a calcium channel blocker that works by relaxing blood vessels and reducing blood pressure.

Phase 1 pipeline

• AD-101 45mg
• AD-102
• AD-104-A
• AD-115A, AD-1151
• AD-116
• AD-116, AD-1161
• AD-1161
• AD-117
• AD-117A
• AD-118, AD-1181
• AD-120
• AD-120A
• AD-2101
• AD-2102
• AD-2111
• AD-2112
• AD-213-A
• AD-213-B
• AD-2131
• AD-2132
• AD-214-02
• AD-2141
• AD-221A and AD-221B
• AD-2281 and AD-2282
• AD-2284
• AD-228A
• AD-228B
• AD-229
• AD-2291
• Administration of AD-227
• Co-administration of AD-227A and AD-227B
• PA-111
• PA-111A